Modification of interleukin-15 serum levels in workers exposed to chemotherapeutic agents

Mediators of Inflammation

Volumn 2005, Issue 1, 2005, Pages 60-62

  Spatari, Giovanna ^a   Fenga, Concettina ^a   Minciullo, Paola Lucia ^a   Di Pasquale, Giuseppe ^a   Cacciola, Anna ^a   Ventura Spagnolo, Elvira ^a   Gangemi, Sebastiano ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; INTERLEUKIN 15;

ADULT; ARTICLE; BLOOD LEVEL; CARCINOGENICITY; CLINICAL ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HEALTH CARE PERSONNEL; HUMAN; IN VIVO STUDY; MALE; MUTAGENICITY; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RISK FACTOR; TERATOGENICITY;

ADULT; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-15; MALE; MEDICAL STAFF; MIDDLE AGED; OCCUPATIONAL EXPOSURE;

EID: 21744452700     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1155/MI.2005.60     Document Type: Article

References (5)

1. Merler E, Villa L, Lucchini R. Pathological effects due to antineoplastic drugs in workers engaged in their production, preparation or administration. Med Lav. 1996;87(3):207-221.
2. Alessio L, Apostoli P, Draicchio F, et al. Prevention of risks from occupational exposures to antineoplasticdrugs: consensus document. Int J Occup Environ Health. 1997;3(1):84.
3. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97(1):14-32.
4. Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA. 2004;101(7):1969-1974.
5. Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol. 1998;161(12):6977-6984.